Haemonetics Corp (HAE) Stock
Key stats
- Market cap
- $5.28B
- Price / Earnings ratio
- 55.3x
- EPS (TTM)
- $0.52
- Volume
- Loading
- 52-week high
- $123.77
- 52-week low
- $48.98
- Next earnings report
- 5 Nov 2026
Source: third-party data provider, as of October 24, 2026
Compare with HAE
Recent news
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
HAE
Haemonetics Gains 149.3% in a Year: What's Driving the Rally?
Haemonetics Gains 149.3% in a Year: What's Driving the Rally?
HAE
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
HAE
Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term
Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term
HAENews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 59.60
- MACD 12/26/9
- 3.92
- EMA 9 of MACD
- 4.04
- MACD histogram
- -0.13
- SMA 50
- $107.52
- Price above SMA 50
- EMA 50
- $106.22
- Price above EMA 50
- SMA 200
- $77.49
- Price above SMA 200
- EMA 200
- $84.53
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2026Earnings
The market is expecting earnings per share of $1.40 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
HAEHaemonetics Gains 149.3% in a Year: What's Driving the Rally?
Haemonetics Gains 149.3% in a Year: What's Driving the Rally?
HAEIs it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
HAEWhy Haemonetics (HAE) is a Top Momentum Stock for the Long-Term
Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term
HAE
Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength?
Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength?
HAE
HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today?
HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today?
HAE
Haemonetics shares jump as CSL sets 2027 rollout of plasma devices
Haemonetics shares jump as CSL sets 2027 rollout of plasma devices
HAE
PAHC vs. HAE: Which Stock Is the Better Value Option?
PAHC vs. HAE: Which Stock Is the Better Value Option?
HAE
Haemonetics (HAE) is a Top-Ranked Momentum Stock: Should You Buy?
Haemonetics (HAE) is a Top-Ranked Momentum Stock: Should You Buy?
HAE
PAHC vs. HAE: Which Stock Should Value Investors Buy Now?
PAHC vs. HAE: Which Stock Should Value Investors Buy Now?
HAENews tone: automated (AI) classification of the article's content, not a price prediction.
About Haemonetics Corp
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Christopher A. Simon | CEO, President & Director | 1964 |
| Mr. James C. D'Arecca CPA | CFO, Executive VP & Financial Officer | 1971 |
| Mr. Frank W. Chan Ph.D. | Executive VP & COO | 1970 |
| Ms. Michelle L. Basil Esq., J.D. | Executive VP, General Counsel & Secretary | 1973 |
| Mr. Roy Galvin | Executive VP & Chief Commercial Officer | 1970 |
| Ms. Farris Maryanne E. Maunsell | VP, Chief Accounting Officer & Principal Accounting Officer | 1976 |
| Ms. Olga Guyette | VP of IR & Treasury | — |
| Mr. Josh Gitelson | Senior Director of Global Communications | — |
| Mr. Rajeev Varma | Senior Vice President of Strategy & Corporate Development | — |
| Ms. Laurie A. Miller | Senior VP & Chief Human Resources Officer | 1974 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of October 24, 2026
Technical indicators
- RSI 14
- 59.60
- MACD 12/26/9
- 3.92
- EMA 9 of MACD
- 4.04
- MACD histogram
- -0.13
- SMA 50
- $107.52
- Price above SMA 50
- EMA 50
- $106.22
- Price above EMA 50
- SMA 200
- $77.49
- Price above SMA 200
- EMA 200
- $84.53
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst views
7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $86.00
- Average
- $123.29
- High
- $140.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -4.0 | -27.6 | +5.7 | |||||||||
| 2022 | -11.6 | +18.2 | +9.9 | -20.6 | +24.5 | +4.6 | +3.2 | +9.0 | -0.5 | +12.0 | +1.6 | -7.3 |
| 2023 | +9.6 | -7.8 | +7.2 | +1.1 | +2.1 | -1.7 | +10.0 | -2.7 | -0.7 | -3.3 | -6.4 | +1.5 |
| 2024 | -10.2 | -6.4 | +15.1 | +8.4 | -8.7 | -2.7 | +8.8 | -16.1 | +7.1 | -9.9 | +22.4 | -10.7 |
| 2025 | -11.9 | -1.0 | -2.4 | +0.0 | +7.5 | +8.5 | -3.0 | -27.1 | -9.0 | +2.5 | +61.8 | -1.0 |
| 2026 | -16.7 | -3.7 | -11.8 | +6.8 | +14.4 | +11.6 | +14.3 | +18.8 | +3.3 | +11.3 |
